Last reviewed · How we verify
Supra-therapeutic Dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Supra-therapeutic Dose (Supra-therapeutic Dose) — Chiesi Farmaceutici S.p.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Supra-therapeutic Dose TARGET | Supra-therapeutic Dose | Chiesi Farmaceutici S.p.A. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Supra-therapeutic Dose CI watch — RSS
- Supra-therapeutic Dose CI watch — Atom
- Supra-therapeutic Dose CI watch — JSON
- Supra-therapeutic Dose alone — RSS
Cite this brief
Drug Landscape (2026). Supra-therapeutic Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/supra-therapeutic-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab